- Home
- RPD vs XNCR Comparison
RPD vs XNCR Comparison
Compare RPD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- XNCR
- Stock Information
- Founded
- RPD 2000
- XNCR 1997
- Country
- RPD United States
- XNCR United States
- Employees
- RPD N/A
- XNCR N/A
- Industry
- RPD Computer Software: Prepackaged Software
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- XNCR Health Care
- Exchange
- RPD Nasdaq
- XNCR Nasdaq
- Market Cap
- RPD 1.2B
- XNCR 1.1B
- IPO Year
- RPD 2015
- XNCR 2013
- Fundamental
- Price
- RPD $14.49
- XNCR $14.00
- Analyst Decision
- RPD Hold
- XNCR Buy
- Analyst Count
- RPD 21
- XNCR 11
- Target Price
- RPD $24.00
- XNCR $24.50
- AVG Volume (30 Days)
- RPD 953.3K
- XNCR 1.5M
- Earning Date
- RPD 11-04-2025
- XNCR 11-05-2025
- Dividend Yield
- RPD N/A
- XNCR N/A
- EPS Growth
- RPD N/A
- XNCR N/A
- EPS
- RPD 0.35
- XNCR N/A
- Revenue
- RPD $858,667,000.00
- XNCR $157,218,000.00
- Revenue This Year
- RPD $2.75
- XNCR $22.09
- Revenue Next Year
- RPD $3.21
- XNCR N/A
- P/E Ratio
- RPD $41.36
- XNCR N/A
- Revenue Growth
- RPD 3.08
- XNCR 54.77
- 52 Week Low
- RPD $14.13
- XNCR $6.92
- 52 Week High
- RPD $44.48
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- RPD 25.71
- XNCR 54.37
- Support Level
- RPD $18.00
- XNCR $13.30
- Resistance Level
- RPD $18.82
- XNCR $15.50
- Average True Range (ATR)
- RPD 0.72
- XNCR 1.16
- MACD
- RPD -0.39
- XNCR -0.17
- Stochastic Oscillator
- RPD 7.46
- XNCR 48.72
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.